<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We performed [<z:chebi fb="0" ids="36939">18F</z:chebi>]<z:chebi fb="0" ids="49163">6-fluoro-L-dopa</z:chebi> (6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e>) and [<z:chebi fb="4" ids="36929">11C</z:chebi>]raclopride (RAC) PET studies in six patients with <z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>) (age, 17 to 61 years; duration of illness, 3 to 10 years), <z:mpath ids='MPATH_458'>normal</z:mpath> controls (n = 10 in 6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e>-PET, n = 8 in RAC-PET), and patients with idiopathic <z:hpo ids='HP_0001300'>parkinsonism</z:hpo> (n = 15 in 6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e>-PET) </plain></SENT>
<SENT sid="1" pm="."><plain>The youngest patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> had prominent <z:hpo ids='HP_0001332'>dystonia</z:hpo> and pyramidal features (type 1 MJD), whereas the remainder were prominently ataxic (types 2 and 3 MJD) </plain></SENT>
<SENT sid="2" pm="."><plain>Striatal RAC binding was <z:mpath ids='MPATH_458'>normal</z:mpath> in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Striatal 6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e> influx constants (Ki) were low in the range of idiopathic <z:hpo ids='HP_0001300'>parkinsonism</z:hpo> in two patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> (youngest and oldest patients), whereas striatal Ki were <z:mpath ids='MPATH_458'>normal</z:mpath> in the remaining patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The impairment of the nigrostriatal dopaminergic pathway did not correlate with the phenotype, CAG repeat length, disease duration, or <z:hpo ids='HP_0011007'>age of onset</z:hpo> of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Our results suggest that striatal D2 receptors are <z:mpath ids='MPATH_458'>normal</z:mpath> and the nigral damage is diverse in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
</text></document>